Aberrant molecular properties shared by familial Parkinson's disease-associated mutant UCH-L1 and carbonyl-modified UCH-L1.
about
Ubiquitin C-terminal hydrolase L1 (UCH-L1): structure, distribution and roles in brain function and dysfunctionIt Is All about (U)biquitin: Role of Altered Ubiquitin-Proteasome System and UCHL1 in Alzheimer DiseaseDeubiquitinating enzymes in cellular signaling and disease regulationUCHL1 deficiency exacerbates human islet amyloid polypeptide toxicity in β-cells: evidence of interplay between the ubiquitin/proteasome system and autophagySmall changes huge impact: the role of protein posttranslational modifications in cellular homeostasis and diseaseHeterogeneous expression and functional relevance of the ubiquitin carboxyl-terminal hydrolase L1 in melanoma.Structure of transmembrane domain of lysosome-associated membrane protein type 2a (LAMP-2A) reveals key features for substrate specificity in chaperone-mediated autophagy.The ubiquitin-specific protease 14 (USP14) is a critical regulator of long-term memory formation.Modelling the role of UCH-L1 on protein aggregation in age-related neurodegeneration.In vivo transduction of neurons with TAT-UCH-L1 protects brain against controlled cortical impact injury.Cyclopentenone prostaglandin-induced unfolding and aggregation of the Parkinson disease-associated UCH-L1.Lysosomes and α-synuclein form a dangerous duet leading to neuronal cell death.β-cell dysfunctional ERAD/ubiquitin/proteasome system in type 2 diabetes mediated by islet amyloid polypeptide-induced UCH-L1 deficiency.The ubiquitin C-terminal hydrolase L1 (UCH-L1) C terminus plays a key role in protein stability, but its farnesylation is not required for membrane association in primary neurons.N-terminal truncated UCH-L1 prevents Parkinson's disease associated damage.Aberrant interaction between Parkinson disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagyProtein carbonylation and metabolic control systems.Lysosomal putative RNA transporter SIDT2 mediates direct uptake of RNA by lysosomes.Ubiquitin C-terminal hydrolase L1 (UCH-L1) acts as a novel potentiator of cyclin-dependent kinases to enhance cell proliferation independently of its hydrolase activity.S-nitrosylation of UCHL1 induces its structural instability and promotes α-synuclein aggregation.Parkinson disease: a role for autophagy?Defective autophagy in Parkinson's disease: role of oxidative stress.Could dysregulation of UPS be a common underlying mechanism for cancer and neurodegeneration? Lessons from UCHL1.Aberrant autophagy and parkinsonism: does correction rescue from disease progression?UCH-L1 Inhibition Decreases the Microtubule-Binding Function of Tau Protein.Inhibition of UCH-L1 in oligodendroglial cells results in microtubule stabilization and prevents α-synuclein aggregate formation by activating the autophagic pathway: implications for multiple system atrophy.Life and death in the trash heap: The ubiquitin proteasome pathway and UCHL1 in brain aging, neurodegenerative disease and cerebral Ischemia.KSHV LANA and EBV LMP1 induce the expression of UCH-L1 following viral transformation.Ubiquitin C-terminal hydrolase-L1 (UCH-L1) as a therapeutic and diagnostic target in neurodegeneration, neurotrauma and neuro-injuries.PU.1-dependent regulation of UCH L1 expression in B-lymphoma cells.Ubiquitin editing enzyme UCH L1 and microtubule dynamics: implication in mitosis.Identification of autoantigens specific for systemic lupus erythematosus with central nervous system involvement.Modification of ubiquitin-C-terminal hydrolase-L1 by cyclopentenone prostaglandins exacerbates hypoxic injury.Association of ubiquitin carboxy-terminal hydrolase-L1 in cerebrospinal fluid with clinical severity in a cohort of patients with Guillain-Barré syndrome.
P2860
Q26741828-65BB0884-B6BC-49D2-A97B-4B0A21D06AA7Q26765816-EFEAABA4-83DB-43E1-B07A-5824C16E4137Q26801232-3D221813-1004-4CD5-ACB0-737BD1246313Q28118734-42F37654-7D45-44F4-ADD6-5357708BF429Q28396109-28C6B0B4-626A-433A-A342-0EC67FD099C2Q30317812-A107FC97-2B52-4316-A867-B0C335E3BBE3Q30368088-2FB66A17-2772-4326-BE2F-EE8D8BCD1CF4Q30421989-DC12DE24-825B-46F9-8B33-F19DBC84DCC1Q33719548-E0F4B222-6AEA-4216-A9BF-C388A3DA4F7CQ33724954-6C8E7D51-9D0F-4463-979F-3162973691C3Q33859389-36BC3D0C-A279-45DF-8827-D8C5D0592A2DQ34043163-667A0C5E-AD3D-4E18-9295-79509C7E9C12Q34448671-3F8BF517-1F11-47F7-84D3-6C7DA139694CQ34774553-314D378C-1257-4616-83FC-EE1D9BCF64FDQ35193829-D7666D3B-DAA7-43D4-88C3-D38CA80D96D3Q35676668-B17B92B8-C967-42AF-95E4-A338DF45165EQ36129390-FBCB2DF1-962E-43C3-9D5D-D70801B56498Q36810938-AF997E91-A2E1-44EF-A524-E74DDB3494D0Q36812366-59FD736F-5B38-4AF5-AE30-F7F2CCFD8C5BQ37704633-6E16C032-A60E-4456-BFA1-B7D12EDF24A6Q37723226-C6B41BC0-ACA3-40F9-B437-2B8989597DEFQ38035191-6F6D8DF9-5844-4CEE-94AE-FC688B825014Q38108538-82972BC0-CF2F-4EF5-96A0-6B0830BD0DBDQ38212199-7D0108DF-9204-423C-B64E-661B9B4D6F4BQ38829786-0A64DB22-78E1-41A4-80EB-C66247A963CCQ38872092-E7E2318F-4EE2-4170-98B1-A49A5C96878CQ38972179-1271A4E5-435D-4C82-B274-1ECA791C2F6AQ39046910-9948F7E1-B0DB-446F-B7AF-0144060F2285Q39257016-406D68D8-D827-4686-B64C-2CEB25CCD5EAQ39556264-D6685AF4-5BC5-449C-9403-D013746A9537Q39738670-CFE090CA-2284-440B-8E0D-62873ED1BE73Q39760458-760DDE79-6386-46A7-82FD-6C40E4948C1BQ41598067-8C670033-433D-4ED1-8AB6-A21F8B1D4F14Q48297662-5DFC6C2B-6852-4128-B411-F28A597D316C
P2860
Aberrant molecular properties shared by familial Parkinson's disease-associated mutant UCH-L1 and carbonyl-modified UCH-L1.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Aberrant molecular properties ...... and carbonyl-modified UCH-L1.
@en
type
label
Aberrant molecular properties ...... and carbonyl-modified UCH-L1.
@en
prefLabel
Aberrant molecular properties ...... and carbonyl-modified UCH-L1.
@en
P2093
P2860
P356
P1476
Aberrant molecular properties ...... and carbonyl-modified UCH-L1.
@en
P2093
Aiko Kinugawa
Keiji Wada
Kenko Uchida
Mikako Sakurai
Rieko Setsuie
Takeshi Mitsui
Tomohiro Kabuta
P2860
P304
P356
10.1093/HMG/DDN037
P577
2008-02-04T00:00:00Z